Issue 9, 2016

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

Abstract

The indoleamine 2,3-dioxygenase (IDO) mediated kynurenine pathway of tryptophan degradation is identified as an important immune effector pathway in tumor cells to escape a potentially effective immune response. IDO affects the differentiation and proliferation of T cells, triggering downstream signaling through GCN2, mTOR and AhR. Therefore, IDO is an attractive target for cancer immunotherapy. IDO inhibitors exhibit potent anticancer activities and might be very useful in combination with chemotherapy, radiotherapy or immunotherapy to trigger the rapid regression of aggressive tumors. However, the development of IDO pharmacological inhibitors has been a challenging work. This review highlights recent advances (2010–2015) in research related to the role of IDO in immune escape and pathogenic inflammation in cancer, and novel small-molecule IDO inhibitors with an emphasis on their chemical structures and modes of action.

Graphical abstract: IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

Associated articles

Article information

Article type
Review Article
Submitted
25 Nov 2015
Accepted
27 Dec 2015
First published
05 Jan 2016

RSC Adv., 2016,6, 7575-7581

Author version available

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

S. Qian, M. Zhang, Q. Chen, Y. He, W. Wang and Z. Wang, RSC Adv., 2016, 6, 7575 DOI: 10.1039/C5RA25046C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements